Accurate diagnosis of neurodegenerative diseases requires a multimodal approach combining clinical assessment, biomarker analysis, neuroimaging, and increasingly, digital health technologies. This overview provides a comprehensive guide to the diagnostic landscape for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other related conditions. [@biomarkers2023]
The diagnostic paradigm has shifted dramatically in recent years, moving from purely clinical diagnosis toward biomarker-confirmed detection that can identify pathology even before clinical symptoms emerge [1](https://doi.org/10.1016/S1474-4422(23)00408-4). [@moca2005]
Diagnostic Modalities
Clinical Assessment
Clinical evaluation remains the cornerstone of neurodegenerative disease diagnosis. Neurologists and geriatricians assess: [@updrs2003]
Functional Independence: Ability to perform activities of daily living
...
Diagnostic Methods Overview
Introduction
Accurate diagnosis of neurodegenerative diseases requires a multimodal approach combining clinical assessment, biomarker analysis, neuroimaging, and increasingly, digital health technologies. This overview provides a comprehensive guide to the diagnostic landscape for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other related conditions. [@biomarkers2023]
The diagnostic paradigm has shifted dramatically in recent years, moving from purely clinical diagnosis toward biomarker-confirmed detection that can identify pathology even before clinical symptoms emerge [1](https://doi.org/10.1016/S1474-4422(23)00408-4). [@moca2005]
Diagnostic Modalities
Clinical Assessment
Clinical evaluation remains the cornerstone of neurodegenerative disease diagnosis. Neurologists and geriatricians assess: [@updrs2003]
Functional Independence: Ability to perform activities of daily living
Standardized scales include the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) for cognition [2](https://pubmed.ncbi.nlm.nih.gov/15954109/), Unified Parkinson's Disease Rating Scale (UPDRS) for PD [3](https://pubmed.ncbi.nlm.nih.gov/11136110/), and Clinical Dementia Rating (CDR) for dementia staging [4](https://pubmed.ncbi.nlm.nih.gov/8187591/). [@clinical1982]
Neuroimaging
Neuroimaging provides crucial information about brain structure and function: [@hippocampal2002]
Structural MRI: [@datspect2014]
Assesses regional brain atrophy patterns
Rules out treatable causes of dementia
Differentiates between AD, FTD, vascular dementia
Hippocampal atrophy is a key AD biomarker [5](https://pubmed.ncbi.nlm.nih.gov/11806130/)
PET Imaging: [@atn2018]
Amyloid PET (florbetapir, flutemetamol, florbetaben) detects amyloid plaques
[Tau](/proteins/tau) PET (flortaucipir) visualizes neurofibrillary tangles
FDG-PET shows hypometabolism patterns specific to each disease
Dopamine transporter SPECT (DaT-SPECT) confirms dopaminergic deficit in PD [6](https://pubmed.ncbi.nlm.nih.gov/24366148/)
Advanced Techniques: [@apoe2010]
Diffusion tensor imaging (DTI) reveals white matter integrity
Neurofilament light chain (NfL) and phosphorylated heavy chain (pNfH)
Prognostic and disease progression markers
Genetic Testing
Genetic analysis identifies risk factors and confirms monogenic forms:
[APOE](/proteins/apoe) genotyping: E4 allele increases AD risk 3-4 fold [8](https://pubmed.ncbi.nlm.nih.gov/19968377/)
Monogenic testing: [APP](/entities/app-protein), [PSEN1](/entities/psen1), [PSEN2](/entities/psen2) for AD; [LRRK2](/entities/lrrk2), [GBA](/entities/gba), SNCA for PD; [C9orf72](/entities/c9orf72), SOD1, FUS for ALS
Polygenic risk scores: Aggregate risk from multiple variants
Digital Biomarkers
Wearable and digital technologies enable continuous monitoring: